Nalaganje...

Targeting SDF-1/CXCL12 with a ligand that prevents activation of CXCR4 through structure based drug design

[Image: see text] CXCL12 is an attractive target for clinical therapy because of its involvement in autoimmune diseases, cancer growth, metastasis, and neovascularization. Tyrosine sulfation at three positions in the CXCR4 N-terminus is crucial for specific, high-affinity CXCL12 binding. An NMR stru...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Veldkamp, Christopher T., Ziarek, Joshua J., Peterson, Francis C., Chen, Yu, Volkman, Brian F.
Format: Artigo
Jezik:Inglês
Izdano: 2010
Teme:
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC2941798/
https://ncbi.nlm.nih.gov/pubmed/20459090
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/ja1002263
Oznake: Označite
Brez oznak, prvi označite!